Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?
Kleiman
Neal S
NS
Cardiology, Baylor College of Medicine, and the Cardiac Catheterization Laboratories, Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX 77030, USA. nkleiman@bcm.tmc.edu
D000077144:Clopidogrel; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D009204:Myocardial Revascularization / Q000295:instrumentation; D010455:Peptides / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010976:Platelet Count; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies; D055502:Secondary Prevention; D015607:Stents; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077144:Clopidogrel; D000077542:Eptifibatide; D013988:Ticlopidine